Therapeutic potential of RNA interference against cellular targets of HIV infection.
Therapeutic potential of RNA interference against cellular targets of HIV infection.
复制标题
RNA干扰HIV感染的细胞靶标的治疗潜力。
DOI：
10.1007/s12033-007-9000-0
复制
发表时间：
2007-11
影响因子：
2.6
通讯作者：
Sirois P
中科院分区：
文献类型：
--
作者：
Zhang J;Wu YO;Xiao L;Li K;Chen LL;Sirois P
RNA干扰不仅在寻找药物开发的新靶点方面非常有前途，siRNA/shRNA本身也可以直接用作治疗剂。在通过RNA干扰抑制病毒感染方面，已经对病毒靶标和细胞蛋白进行了评估。这一领域的大多数早期研究都选择了RNA干扰的病毒靶标。然而，最近的努力主要集中在RNA沉默的细胞蛋白上，因为人们意识到各种病毒反应大大减少了siRNA的影响。随着siRNA应用的临近，许多与HIV感染相关的新的细胞靶点被识别出来。SiRNA/shRNA在艾滋病治疗中的价值在很大程度上取决于对艾滋病毒复制生物学的更好了解。利用siRNA/shRNA识别细胞过程的努力为我们理解艾滋病毒感染是如何发生的提供了一些新的线索。此外，相对特异的效应和设计的简单性使siRNA/shRNA本身成为有利的药物先导。
RNA interference is not only very promising in identifying new targets for drug development, siRNA/shRNA themselves may be directly used as therapeutic agents. In inhibiting viral infections by RNA interference, both viral targets and cellular proteins have been evaluated. Most of the early studies in this field had chosen viral targets for RNA interference. However, recent efforts are mainly focusing on cellular proteins for RNA silencing due to the realization that a variety of viral responses substantially minimize siRNA effects. With the application of siRNA approaching, many new cellular targets relevant to HIV infection have been identified. The value of siRNA/shRNA in the treatment of AIDS is largely dependent on better understanding of the biology of HIV replication. Efforts in the identification of cellular processes with the employment of siRNA/shRNA have shed some new lights on our understanding of how HIV infection occurs. Furthermore, the relative specific effects and simplicity of design makes siRNA/shRNA themselves to be favorable drug leads.
登录
查看更多内容
影响因子：
82.9
作者：
Gaggar, A;Shayakhmetov, DM;Lieber, A
通讯作者：
Lieber, A
影响因子：
3.5
作者：
Ji, JM;Wernli, M;Erb, P
通讯作者：
Erb, P
影响因子：
15.9
作者：
Hauber, I;Bevec, D;Hauber, J
通讯作者：
Hauber, J
影响因子：
3.7
作者：
Ammosova, T;Berro, R;Nekhai, S
通讯作者：
Nekhai, S
影响因子：
5.4
作者：
Arrighi, JF;Pion, M;Piguet, V
通讯作者：
Piguet, V